Diagnosis

Hypoparathyroidism

Underproduction of PTH resulting in hypocalcemia, hyperphosphatemia, and neuromuscular irritability.

Etiology

Cause [hap]

Pathophysiology [soa]

  1. Calcium homeostasis is regulated by:

    • Parathyroid hormone (PTH)

    • Vitamin D metabolites

    • Calcitonin

  2. The mechanism control calcium transport in bone, kidneys, and the GI tract

  3. Hypoparathyroidism --> PTH fail to rise in response to hypocalcemia --> no mobilization of the skeleton or increase in renal resorption --> hypocalcemia

Complications [soa]

Epidemiology

Incidence per 100.000 [3tz][29e][knq][hap][iqw][gdk][nei][1ug]

Epidemiology chart for Incidence

Prevalence per 100.000 [3tz][29e][knq][hap][iqw][gdk][nei][1ug]

Epidemiology chart for Prevalence

Approach

Treatment

  1. Acute onset with severe hypocalcemia: intravenous calcium administration [soa]

    • IV calcium bolus of 90-180 mg infused over 10-20 minutes with cardiac monitoring

    • Maintenance IV calcium infusion of 900 mg Ca in 1 L of saline at a rate of 50 mL/hr

    • Corrected calcium = measured total calcium + [0.8 x(4-measured serum albumin)]

  2. Chronic hypoparathyroidism: [kdq]

    • Treatment goals:

      • Keep patients asymptomatic

      • Maintain the calcemia slightly below or in the lower normal range

      • Calciuria up to 4 mg/kg/day

    • Calcium supplementation:

      • Calcium carbonate 2.5-7.5 g/day

      • Calcium citrate 5-15 g/day

    • Vitamin D

      • Calcitriol 0.25-2 mcg/day

      • Cholecalciferol 10,000 - 100,000 UI/day

    • Magnesium supplementation: 250-1,000 mg/day

    • Phosphate binder: Sevelamer 800 mg x 3

    • Thiazide diuretic: 12,5-100 mg/day

    • Subcutaneous PTH injection 25-100 mcg/day

Differential diagnoses

Clostridium tetani, Hyperkalemia, Hyperphosphatemia, Hyperventilation, Hypocalcemia, Hypocapnia, Hypokalemia, Hypomagnesemia, Hypoparathyroidism, Milk-alkali syndrome


References

[1] Pasieka JL, Wentworth K, Yeo CT, Cremers S, Dempster D, Fukumoto S, Goswami R, Houillier P, Levine MA, Pasternak JD, Perrier ND, Sitges-Serra A, Shoback DM. Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review. J Bone Miner Res. 2022 Dec;37(12):2586-2601.

[2] Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013 Dec;28(12):2570-6.

[3] Hans SK, Levine SN. Hypoparathyroidism. [Updated 2024 Feb 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441899/

[4] Bjornsdottir S, Ing S, Mitchell DM, Sikjaer T, Underbjerg L, Hassan-Smith Z, Sfeir J, Gittoes NJ, Clarke L BL. Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism. J Bone Miner Res. 2022 Dec;37(12):2602-2614.

[5] Vadiveloo T, Donnan PT, Leese GP. A Population-Based Study of the Epidemiology of Chronic Hypoparathyroidism. J Bone Miner Res. 2018 Mar;33(3):478-485.

[6] Cipriani C, Pepe J, Biamonte F, Manai R, Biondi P, Nieddu L, Cianferotti L, Brandi ML, Minisola S. The Epidemiology of Hypoparathyroidism in Italy: An 8-Year Register-Based Study. Calcif Tissue Int. 2017 Mar;100(3):278-285.

[7] Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016 Jun;101(6):2284-99.

[8] Cianferotti L, Parri S, Gronchi G, Marcucci G, Cipriani C, Pepe J, Raglianti M, Minisola S, Brandi ML. Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database. Calcif Tissue Int. 2018 Aug;103(2):144-150.

[9] Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53.

[10] Sakane EN, Vieira MCC, Vieira GMM, Maeda SS. Treatment options in hypoparathyroidism. Arch Endocrinol Metab. 2022 Nov 11;66(5):651-657.

Scroll to top